FDA NDA · NDA208715

CABAZITAXEL

Sponsor: SANDOZ

APPLICATION

NDA208715

TYPE

NDA

ROUTE

INTRAVENOUS

DOSAGE FORM

SOLUTION

MARKETING STATUS

None (Tentative Approval)

Products

CABAZITAXEL · ReferenceNone (Tentative Approval)

CABAZITAXEL 60MG/6ML (10MG/ML) · SOLUTION · INTRAVENOUS

CABAZITAXEL · ReferenceNone (Tentative Approval)

CABAZITAXEL 45MG/4.5ML (10MG/ML) · SOLUTION · INTRAVENOUS

2023-10-27Type 3 - New Dosage Form · Original · standard — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.